Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab

Immune check point inhibitor has made far-reaching changes in the management of lung adenocarcinoma improving drastically the prognosis. We present a case of a 50 years old women beneficiary of pembrolizumab who has suffered an acute pneumonitis diagnosed with CT imaging the days following the initi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiba, Zahi, Abdelmoughit, Hosni, Zaynab, Iraqi Houssaini, Hounaida, Jerguigue, Rachida, Latib, Youssef, Omor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411188/
https://www.ncbi.nlm.nih.gov/pubmed/36032207
http://dx.doi.org/10.1016/j.radcr.2022.07.083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411188/
https://www.ncbi.nlm.nih.gov/pubmed/36032207
http://dx.doi.org/10.1016/j.radcr.2022.07.083

Ejemplares similares